Welcome to our dedicated page for Iradimed SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRadimed Corporation (IRMD) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents provide structured detail on financial performance, governance, and material events related to iRadimed’s business of MRI-compatible medical devices, including non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems.
Among the key filings are Form 8-K current reports, which iRadimed uses to announce events such as quarterly financial results, changes in its Board of Directors, and outcomes of stockholder meetings. For example, Form 8-K filings have reported record quarterly revenue, the use of non-GAAP financial measures like non-GAAP net income and free cash flow, the completion of a new facility in Orlando, Florida, and the retirement and appointment of directors. Other 8-Ks furnish press releases that detail FDA 510(k) clearance for the MRidium 3870 IV Infusion Pump System and summarize voting results from the Annual Meeting of Stockholders.
Filings also disclose listing information for iRadimed’s common stock, including its trading symbol IRMD and its listing on the NASDAQ Global Market, with one filing referencing the NASDAQ Capital Market. Governance-related sections describe board committee assignments, independence determinations, and advisory votes on executive compensation. These documents collectively give insight into how the company is overseen and how major decisions are communicated to investors.
On Stock Titan, iRadimed’s SEC filings are paired with AI-powered summaries that explain the contents of lengthy documents in plain language. Users can quickly see the main points of quarterly earnings announcements, board changes, and stockholder votes without reading every page. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while AI-generated highlights help readers identify sections related to financial condition, risk factors, and corporate actions. For those researching IRMD’s regulatory history and ongoing obligations, this page offers a focused view of its official SEC reporting.
Iradimed Corporation reported an insider equity transaction by director James B. Hawkins. On December 11, 2025, 905 shares of common stock were acquired following the conversion of restricted stock units, at an exercise price of $0. After this transaction, Hawkins directly beneficially owns 29,647 shares of Iradimed common stock.
The derivative position involved 905 restricted stock units that converted into an equal number of common shares on a one-for-one basis. These units were originally granted on December 11, 2024 under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning on December 11, 2025. Following the reported transaction, 906 restricted stock units remain beneficially owned.
Iradimed Corporation’s chief financial officer, John Glenn, reported several personal stock transactions in the company’s common shares on December 11, 2025. He sold 14,468 shares at a weighted average price of $97.26 in multiple trades and an additional 532 shares at $98.09, as part of his ongoing equity activity.
On the same date, 1,812 restricted stock units (RSUs) converted into common stock on a one‑for‑one basis, and 714 shares were withheld at $97.38 to cover tax obligations, leaving him with 8,460 shares of common stock held directly. He also beneficially owns 3,624 RSUs granted under Iradimed’s 2023 Equity Incentive Plan, which vest in three equal annual installments beginning on December 11, 2025.
Iradimed Corporation director Monty K. Allen reported converting 905 restricted stock units into shares of common stock on December 11, 2025, and now directly holds 22,000 shares.
The restricted stock units were granted on December 11, 2024 under Iradimed Corporation's 2023 Equity Incentive Plan and vest in two equal annual installments beginning December 11, 2025; after this transaction, 906 restricted stock units remain, each convertible into one share of common stock upon vesting.
Iradimed Corporation director James B. Hawkins reported the vesting and conversion of restricted stock units into common stock. On December 7, 2025, 1,197 restricted stock units converted into 1,197 shares of Iradimed common stock at an exercise price of $0, reflecting a standard equity grant vesting.
These units were granted on December 7, 2023 under Iradimed's 2023 Equity Incentive Plan and vest in two equal annual installments beginning December 7, 2024. Following this transaction, Hawkins beneficially owns 31,742 shares of Iradimed common stock directly.
IRADIMED Corporation (IRMD) CEO, president, chairman and director Roger E. Susi reported insider sales of common stock on 11/24/2025. Through the Phillip Susi 2008 Dynasty Trust, he sold a total of 5,000 shares in three transactions: 556 shares at a weighted average price of $89.67, 3,558 shares at $90.31, and 886 shares at $91.01, all coded as open market sales.
These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. After the reported transactions, the Phillip Susi 2008 Dynasty Trust beneficially owns 2,307,500 shares, with additional indirect holdings reported through other trusts.
IRADIMED CORP director reports open-market stock sales. A reporting person serving as a director of IRADIMED CORP (ticker IRMD) disclosed several open-market sales of common stock on 11/20/2025. The transactions, all coded as sales, totaled 3,000 shares at prices ranging from $88.00 to $88.50 per share. After these trades, the director beneficially owned 30,545 shares of IRADIMED common stock in direct ownership. This filing is a routine Form 4 disclosure of insider trading activity and does not describe any company-level operational or financial changes.
IRADIMED Corporation (IRMD) CEO Roger E. Susi, who is also a director, chairman and 10% owner, reported indirect sales of company common stock on 11/18/2025. A trust for his benefit, the Phillip Susi 2008 Dynasty Trust, sold 3,184 shares at a weighted average price of $85.29 and 1,816 shares at a weighted average price of $86.12, in transactions coded as open-market sales. These trades were made under a Rule 10b5-1 trading plan adopted on June 16, 2025. After the reported transactions, indirect beneficial holdings remain in multiple trusts, including over two million shares held through the Phillip Susi 2008 Dynasty Trust.
IRADIMED CORP (IRMD) reported an insider transaction on Form 4 by CEO, President, Chairman and Director Roger E. Susi, who is also a 10% owner. On 11/10/2025, he reported two open-market sales of common stock coded “S”.
He sold 2,252 shares at a weighted average price of $84.59 (individual trades ranged from $84.27 to $85.01) and 2,748 shares at a weighted average price of $85.77 (range $85.29 to $86.09). The sales were effected under a Rule 10b5-1 trading plan adopted on June 16, 2025.
Following these transactions, reported indirect holdings include 2,317,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, as disclosed.
IRADIMED CORP (IRMD) filed a Form 4 reporting an insider sale. The company’s Chief Financial Officer sold 10,651 shares of common stock on 11/10/2025, coded “S” for an open-market sale, at a weighted average price of $84.5143. Following the transaction, the reporting person directly holds 2,500 shares. The sale was executed in multiple trades within a price range of $84.25 to $85.18, with the weighted average provided; full trade details are available upon request.
IRADIMED Corp (IRMD) CEO, President, Chairman and Director Roger E. Susi reported open-market sales of common stock on November 3, 2025.
The filing lists six tranches by an indirect holder, the Phillip Susi 2008 Dynasty Trust, including 1,618 shares at a weighted average price of $83.85, 1,335 shares at $83.22, 900 shares at $81.71, 601 shares at $81.28, 446 shares at $79.82, and 100 shares at $84.60. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
Following the reported transactions, the filing shows 2,322,500 shares held indirectly by the Phillip Susi 2008 Dynasty Trust, 162,950 shares held indirectly by the Roger E. Susi Revocable Trust, and 2,062,500 shares held indirectly by the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership of certain securities except to the extent of pecuniary interest.
FAQ
What is the current stock price of Iradimed (IRMD)?
What is the market cap of Iradimed (IRMD)?
